Biguanides, including metformin, buformin, and phenformin, are potential antitumorigenic agents and induce cell death during glucose deprivation, a cell condition that occurs in the tumor microenvironment. Here, we show that this selective killing of glucose-deprived cells is coupled with hyperactivation of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), a negative regulator of translation initiation. We found, in fact, that the 4E-BP1 hyperactivation led to failure of the unfolded protein response (UPR), an endoplasmic reticulum-originated stress signaling pathway for cell survival. We also found that the 4E-BP1-mediated UPR inhibition occurred through a strong inhibition of the mTOR signaling pathway, a proven antitumor target. Importantly, the 4E-BP1 hyperactivation can be also seen in xenografted cancer cells through an in vivo biguanide treatment. Our findings indicate that antitumor action of biguanides can be mediated by 4E-BP1 hyperactivation, which results in UPR inhibition and selective cell killing when glucose is withdrawn. Mol Cancer Ther; 11(5); 1082-91. Ó2012 AACR.
Introduction
Translation initiation, a rate-limiting process in mRNA translation, is essential for cell growth and survival but is often dysregulated in cancer (1) . The process of translation initiation has 2 major regulatory steps. One is assembly of a ternary complex consisting of methionine-charged tRNA, eukaryotic initiation factor (eIF) 2, and GTP, and this assembly is negatively regulated by phosphorylation of eIF2a (a-subunit of eIF2; ref. 1) . The other regulatory step is formation of an eIF4F complex, which binds to the 7-methylguanosine triphosphate (7mGTP)-cap structure at the 5 0 terminus of mRNA and recruits 40S ribosome (1) . The eIF4F complex consists of eIF4E, eIF4G, and eIF4A, and this assembly is inhibited by eIF4E-binding protein 1 (4E-BP1). 4E-BP1 binds to eIF4E and disturbs the eIF4E and eIF4G association. The binding activity of 4E-BP1 is regulated and turned off by phosphorylation mediated by a kinase, mTOR (1) . Recent clinical studies show that mTOR inhibitors can be effective as antitumor agents (2) and that 4E-BP1 plays an important role in suppressing tumor growth by mTOR inhibition (2, 3) .
Glucose deprivation is a cell condition that occurs in the microenvironment of solid tumors due to insufficient blood supply and the large glucose consumption of glycolytic tumor cells (4, 5) . During glucose deprivation, the translation initiation system can be involved in an adaptive cell survival response. In fact, glucose deprivation attenuates the mTOR signaling pathway, which decreases translation initiation by activating the inhibitory protein 4E-BP1 (6) . Glucose deprivation also elicits the unfolded protein response (UPR), an endoplasmic reticulum (ER)-originated stress signaling pathway that reduces global protein synthesis with decreased translation initiation and produces several transcription factors to induce the UPR target genes, such as the ER-resident molecular chaperones glucose-regulated protein 78 (GRP78; refs. 7, 8) .
The UPR signaling pathway is initiated when the ERlocalized transmembrane proteins PKR-like ER kinase (PERK), inositol-requiring 1 (IRE1), and activating transcription factor 6 (ATF6) are activated (8) . Among them, PERK plays a major role in the UPR translational control by phosphorylating eIF2a, an important regulatory mechanism of translation initiation (9, 10) . Phosphorylation of eIF2a reduces global translation and, paradoxically, directs preferential translation of ATF4, a UPR transcription activator (10) . The PERK signaling pathway is further regulated by an ATF4-directed feedback system for eIF2a dephosphorylation, thereby restoring translation to the UPR target transcripts (11) . In addition to this eIF2a-mediated regulation, 4E-BP1-mediated regulation of translation initiation has also been shown to play an important role in the UPR, especially at the late stage during prolonged ER stress (12) . Thus, translation initiation is an important regulatory mechanism for the UPR that is involved in cell survival under stress conditions (13) (14) (15) (16) .
Antidiabetic biguanides, including metformin, buformin, and phenformin, are known as small molecule compounds that reduce blood glucose level by inhibiting glucose synthesis and enhancing its uptake into cells (17, 18) . These behaviors have been associated with activation of AMP-activated protein kinase (AMPK; ref. 17, 18) . It was recently reported that antidiabetic biguanides can exert antiproliferative and proapoptotic effects on different cancer types through AMPK-dependent and AMPK-independent mechanisms (19, 20) . These antidiabetic biguanides have also been shown to inhibit UPR activation and to induce selective cancer cell killing during glucose deprivation (21) . Previous studies have focused on the actions of biguanides under normal growth conditions; however, it is largely unknown how biguanides affect cellular response to glucose deprivation, a representative tumor microenvironmental stress condition. In this study, we show that, during glucose deprivation, biguanides induce hyperactivation of 4E-BP1 through a strong inhibition of the mTOR signaling pathway, which is closely associated with UPR inhibition and selective cytotoxicity.
Materials and Methods

Cell cultures and treatment
Cells were cultured in either RPMI1640 (Wako Pure Chemical Industry; human fibrosarcoma HT1080 and stomach cancer MKN-74 cells) or Dulbecco's Modified Eagle's Medium (Wako Pure Chemical Industry; human cervical cancer HeLa and embryonic kidney 293T cells) supplemented with 10% FBS and 100 mg/mL of kanamycin and were cultured at 37 C in a humidified atmosphere of 5% CO 2 (20, 21) . Cell authentication was not done by the authors within the last 6 months. To analyze several stress conditions, cells were cultured for the indicated time periods in glucose-containing medium in the presence of 10 mmol/L 2-deoxyglucose (2DG; Sigma), 5 or 10 mg/mL of tunicamycin (Nacalai Tesque) or in glucose-free medium (Sigma). Cells were also treated with various concentrations of phenformin (5-500 mmol/L; Sigma), buformin (30-1000 mmol/L; Wako), 10 mmol/L metformin (Sigma) rapamycin (0.3-100 nmol/L; Sigma), and PP242 (0.03-10 mmol/L; Sigma). These compounds were added to culture medium, with the solvent being less than 0.5% of the medium's volume.
RNA interference
Control short interfering RNA (siRNA) and Stealth siRNAs against human 4E-BP1 were purchased from Invitrogen. Lipofectamine RNAi MAX (Invitrogen) was used for transfection.
Immunoblot analysis
Cell lysates were prepared as previously described (22) . The following antibodies were used for immunoblotting: anti-eIF2a (Abcam), anti-phospho eIF2a, anti-4EBP1, anti-phospho-4EBP1 (Ser65; 174A9), anti-phospho-4EBP1 (Thr70), anti-eIF4E, anti-eIF4G, anti-AMPK, anti-phospho-AMPK (Cell Signaling Technology), anti-KDEL (for GRP78 detection; Stressgen), anti-ATF4 (Santa Cruz Biotechnologies), and anti-b-actin (Sigma).
7mGTP affinity purification
HeLa cells were treated in the lysis buffer [50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1 mmol/L EDTA, 1% Triton X-100, Phosphatase Inhibitor Cocktail 1 and 2 (Sigma), and Protease Inhibitor (Sigma)] at 4 C for 30 minutes. Cell extracts (500 mg) were incubated with 7mGTP-conjugated Sepharose beads (GE Healthcare UK Ltd.) in the lysis buffer at 4 C for 2 hours (22) . After 3 washings in the lysis buffer, the beads were boiled with 2ÂSDS sample loading buffer at 100 C. Each sample was analyzed by immunoblot.
Measurement of cells viability
HeLa cells were treated with phenformin, rapamycin, or PP242 in the presence or absence of ER stress inducers (2DG or tunicamycin) for 24 hours. The medium was then replaced with fresh growth medium, and cells were cultured for a further 24 hours. MTT (Sigma) was then added to the culture medium. After 3 hours, the absorbance of each well was determined, as described previously (22) . Relative cell survival was calculated by setting each control absorbance from untreated cells as 100%.
In the case of 4E-BP1 knockdown, HeLa cells were treated with phenformin or buformin in the presence or absence of 2DG for 14 hours. Then, the cells were reseeded to 12-well plates and incubated for 5 days. Afterward, the cell viability was determined by MTT assay.
Reporter assay
HT1080 cells were transfected with a firefly luciferasecontaining reporter plasmid (pGRP78pro160-Luc) that contained the promoter region of grp78 (23) and Renilla luciferase-containing plasmid phRL-CMV (Promega) as an internal control. Relative activity of firefly luciferase to Renilla luciferase (mean AE SD of triplicate determinations) was determined using the Dual-Glo Luciferase Assay System (Promega).
Nuclear and cytoplasmic extract preparation
Cells were fractionated using NE-PER nuclear and cytoplasmic extraction reagents (Pierce), following manufacturer's instruction.
MKN74 xenograft tumors
MKN-74 cells were implanted subcutaneously in the right flank region of 9-week-old BALB/cAJcl-nu/nu mice (n ¼ 6 for evaluation of tumor growth; Charles River Japan, Inc.). The experiments were started approximately 10 days after cell implant when tumors, measured with calipers, reached 150 mm 3 (day 0). Buformin was injected into the tumor for immunohistochemical analysis or was administered daily by oral gavage to evaluate the therapeutic effects of the drug. The length (L) and width (W) of the tumor were measured, and the tumor volume (TV) was calculated as TV ¼ (L Â W Â W)/2. The data are expressed as mean AE SE. After checking the linearity of growth curves of TVs, we conducted a Welch t test between the treatment and control groups using the slopes of the growth curves based on the linear regression.
Results
Hypophosphorylation of 4E-BP1 by biguanides
We carried out immunoblot analysis to determine 4E-BP1 phosphorylation status in HT1080 cells that had been treated for 4 or 8 hours with phenformin in the presence or absence of the hypoglycemia-mimicking agent 2DG (Fig.  1A ). The phosphorylation status was monitored both by band shifts from higher (hyperphosphorylated) to lower apparent molecular weight (hypophosphorylated) with anti-4E-BP1 antibody and by signal intensity with each phosphospecific anti-4E-BP1 antibody at Thr37/46, Ser65, and Thr70. We found that phenformin in combination with 2DG strongly induced hypophosphorylation of 4E-BP1, whereas each single phenformin and 2DG treatment had a weak or marginal effect (Fig. 1A) . Densitometric analysis of band intensities revealed that Ser65 phosphorylation levels of 4E-BP1 reduced to the levels of less than 5% by the combination, although remained 50% or more in the case of each single treatment (Supplementary Table S1 ). Under 2DG stress conditions, induction of ATF4 and GRP78, typical UPR marker proteins, was seen within the time periods, but induction was suppressed in the presence of phenformin (Fig. 1A , Supplementary  Table S1 ). We noted that both hypophosphorylation of 4E-BP1 and suppression of GRP78 induction in 2DG-stressed HT1080 cells occurred at the same phenformin dose (Fig. 1B, Supplementary Table S1 ).
To examine whether phenformin induced 4E-BP1 hypophosphorylation under different ER stressors, we treated HT1080 cells for 4 hours with phenformin, together with 2DG or an N-glycosylation inhibitor tunicamycin (Fig. 1C, Supplementary Table S1 ). In contrast to what we saw in 2DG-stressed cells, phenformin had little effect on either 4E-BP1 phosphorylation status or GRP78 induction in tunicamycin-stressed cells (Fig. 1C , Supplementary Table S1 ). On the other hand, effects similar to those seen for phenformin on 4E-BP1 and GRP78 were also observed in HT1080 cells subjected to glucose withdrawal for 20 hours and in HeLa cells stressed for 4 hours with 2DG ( Fig. 1D and E, Supplementary Table S1 ). In LKB1-defective HeLa cells, LKB1 
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β-Actin being an upstream kinase of AMPK (24) , phenformin had marginal effect on AMPK phosphorylation (Fig. 1E , Supplementary Table S1), suggesting that AMPK activation was unnecessary for phenformin-induced 4E-BP1 hypophosphorylation. Phenformin had only a marginal effect on the phosphorylation states of eIF2a, another translation initiation regulator important for the UPR, in HT1080 cells (Fig. 1F, Supplementary Table  S1 ).
We also examined the effects of other antidiabetic biguanides buformin and metformin on 4E-BP1 phosphorylation status in HT1080 cells (Fig. 2) . Buformin showed essentially the same effects on 4E-BP1 and on ATF4 and GRP78 in 2DG-stressed HT1080 cells, although somewhat higher concentrations than phenformin were required ( Fig. 2A) . Metformin also induced 4E-BP1 hypophosphorylation and suppressed GRP78 induction at as high as 10 mmol/L (Fig. 2B) . Thus, the biguanides, which have an inhibitory activity on UPR activation, can induce strong hypophosphorylation of 4E-BP1 under conditions of 2DG stress and glucose withdrawal.
Involvement of 4E-BP1 in cell death under stress conditions
To examine whether 4E-BP1 has any impact on cytotoxicity induced by 2DG stress and biguanides, we silenced 4E-BP1 expression in HeLa cells using siRNA (Fig. 3A) . The 4E-BP1 knockdown enhanced GRP78 induction under 2DG stress conditions (Fig. 3B) , as we saw in our previous study (22) . Consistent with the protective role of GRP78, the 4E-BP1-silenced cells showed an enhanced cell survival during 2DG stress, as compared with nonsilenced control cells (Fig. 3C and D) . Interestingly, the 4E-BP1-silenced cells also showed enhanced cell survival even after treatment for 18 hours with phenformin (Fig. 3C) or buformin (Fig. 3D ) in the presence of 2DG. In the absence of 2DG, biguanide cytotoxicity was scarcely observed in both control and 4E-BP1-silenced cells. These results suggested that 4E-BP1 could be involved in cell death regulation under the stress conditions.
Hyperactivation of 4E-BP1 by biguanides
To examine whether the hypophosphorylation of 4E-BP1 by biguanides led to increased association with eIF4E, we carried out an mRNA cap structure 7mGTP-binding assay. The 7mGTP-Sepharose was able to pull down essentially the same levels of eIF4E from any lysates of HeLa cells cultured under various conditions (Fig. 4A) . Consistent with the 4E-BP1 hypophosphorylation levels, phenformin caused 4E-BP1 binding to eIF4E in 2DG-stressed cells, but not in tunicamycin-stressed cells (Fig.  4A) . Buformin also increased 4E-BP1 binding to eIF4E in 2DG-stressed cells (Fig. 4B) . Conversely, fewer eIF4G proteins were detected in the eIF4E-containing initiation complex of the phenformin-treated, 2DG-stressed cells (Fig. 4A) . Thus, the hypophosphorylated 4E-BP1 became strongly activated, resulting in disruption of the eIF4E-containing translation initiation complex.
Hyperactivation of 4E-BP1 with mTOR inhibition
Rapamycin and PP242 are different classes of mTOR inhibitors; an allosteric and an active site inhibitors, respectively, that can activate 4E-BP1 by inhibiting mTOR kinase activity (25) . To compare the actions of mTOR inhibitors with those of the biguanides, we conducted a 7mGTP-binding assay using HeLa cells that had been treated for 4 hours with rapamaycin, PP242, or buformin in the presence or absence of 2DG ( were able to activate 4E-BP1 regardless of 2DG addition, but PP242 caused much more 4E-BP1 binding to eIF4E than rapamycin did. The levels of 4E-BP1 activation induced by PP242 were comparable with those induced by buformin under 2DG stress conditions. The hyperactivation of 4E-BP1 was associated with strong cytotoxicity in HeLa cells; indeed, PP242, but not rapamycin, under any conditions tested and buformin under 2DG stress conditions were highly toxic (Fig. 5A) .
We further examined the effects of PP242 on 4E-BP1 hypophosphorylation and UPR activation in HT1080 cells, using 3 different ER stress conditions, 2DG, TM, and glucose withdrawal (Fig. 5B) . PP242 induced 4E-BP1 hypophosphorylation and substantially prevented induction of GRP78 and GRP94, regardless of culture conditions. This observation was further confirmed by our reporter assay, using pGRP78-Luc, which contained a GRP78 promoter region (-160 to þ7) immediately upstream of the firefly luciferase (ref; Fig. 5C ). Indeed, PP242 effectively suppressed 2DG-and tunicamycininduced GRP78 promoter activities in a dose-dependent manner.
Hyperactivation and altered localization of 4E-BP1
To explore the similarity in the actions between biguanides and PP242 further, we examined subcellular localization of 4E-BP1 and eIF4E, using a cell fractionation technique followed by immunoblot analysis (Fig. 5D) . We found that when HT1080 cells were treated with a combination of buformin and 2DG or with PP242 regardless of 2DG addition, 4E-BP1 proteins accumulated in the nucleus. Interestingly, the 4E-BP1 accumulation coincided with decreased accumulation of eIF4E in the nucleus. Phenformin, in the presence of 2DG, also induced nuclear accumulation of 4E-BP1 in HT1080 cells (Supplementary Fig.  S1A ). Furthermore, immunofluorescent staining showed that nuclear accumulation of 4E-BP1 also occurred in HeLa cells treated with phenformin in the presence of 2DG (Supplementary Fig. S1B ). It is important that, unlike biguanides and PP242, rapamycin did not cause such changes in nuclear localization of 4E-BP1 and eIF4E ( Fig.  5D and Supplementary Fig. S1 ).
Activation of 4E-BP1 in xenograft
We further characterized the antitumor activity of buformin using stomach cancer cells, MKN74. As shown in Fig. 6A , buformin showed selective cytotoxicity under 2DG, but not tunicamycin, stress conditions. Buformin induced hypophosphorylation of 4E-BP1 within 4 hours and in a dose-dependent manner in 2DG-stressed cells (Fig. 6B and C) . This 4E-BP1 hypophosphorylation was also seen in cells under glucose withdrawal stress (Fig.  6D) . Furthermore, buformin suppressed 2DG-induced GRP78 and GRP94 (Fig. 6C) . Thus, the typical effects of buformin were seen in MKN74 cells. We also found that giving buformin orally to mice caused weak but statistically significant growth retardation of MKN74 xenografts (Fig. 6E) . The weights of buformin-treated animals decreased by less than 10% by day 7 but were regained afterward (data not shown). Although we had carried out immunohistochemical analysis using MKN74 xenografts after giving buformin orally to mice, clear changes in 4E-BP1 phosphorylation status were not seen with or without the drug treatment. To see the potential of in vivo buformin effect, we then tried intratumor drug injection. Immunohistochemical analysis showed that intratumor injection of buformin decreased detection of phosphospecific (T37/ 46) 4E-BP1, as compared with nonphosphospecific 4E-BP1 ( Fig. 6F and Supplementary Fig. S2 ). In addition, close examination of the data revealed that some heterogeneity in the staining for phosphorylated 4E-BP1 was seen even in the control specimen, suggesting that 4E-BP1 phosphorylation status could be fluctuated with cellular states (e.g., necrosis) in intratumor conditions.
Discussion
Recent studies have shown that antidiabetic biguanides, particularly metformin, can exert in vitro and in vivo antitumor activity through multiple modes of action (19) (20) (21) . Of interest is their ability to disrupt the UPR during glucose deprivation because it can lead to selective cell killing under the particular tumor microenvironment (21, 27) . In this study, we have shown that the UPR inhibitory action, as well as cytotoxicity of biguanides, can be mediated by 4E-BP1 hyperactivation during glucose deprivation. Such 4E-BP1 hyperactivation can also be induced in xenoplanted cancer cells by intratumor administration of buformin (Fig. 6F) . Furthermore, mechanistic analysis with the different mTOR inhibitors types PP242 and rapamaycin suggested that strongly inhibiting the mTOR signaling pathway contributes to the 4E-BP1 hyperactivation induced by biguanides.
Our present findings showed that hyperactivation of 4E-BP1 can be involved in preventing UPR activation under stress conditions. This UPR inhibitory action may be associated with the translation repressor activity of 4E-BP1. In fact, we observed strong inhibition of global protein synthesis with 4E-BP1 hyperactivation in cells treated with phenformin and 2DG (Supplementary Data S3). In addition, overexpression of 4E-BP1 by transfection can attenuate the UPR activation, depending on the functional domain of the eIF4E binding site, which is necessary for translation repressor activity (22) . In this context, it is important to note that proper activation of 4E-BP1 is necessary for translation control at the late stage of the UPR (12, 22, 28, 29) . Indeed, prolonged ER stress elicits this necessary 4E-BP1 activation (22, 28, 29) . Thus, dysregulated, drug-induced hyperactivation of 4E-BP1 may disrupt the translation regulation mechanisms that govern the UPR. More generally, hyperactivated 4E-BP1 can suppress translation initiation through binding to eIF4E, an oncogenic protein important for tumor cell survival. It has been reported that various cancer cell lines show increased eIF4E expression and that overexpression of eIF4E causes malignant transformation of cultured cells (30) . It is also known that eIF4E preferentially stimulates translation of a subset of mRNAs that play important roles in cell growth (30) . Consistently, small compounds that inhibit eIF4E function have been reported to suppress cancer cell growth (30, 31) . Therefore, in addition to preventing the UPR, inhibiting eIF4E function can explain the antitumor activity of biguanides through strong activation of 4E-BP1. In this regard, eIF4E can localize in the cytoplasm and the nucleus (32) , and nuclear eIF4E is known to play a role in mRNA export from the nucleus (33) . Such nucleusspecific function of eIF4E might also be an antitumor target, because biganides as well as PP242 can decrease eIF4E protein levels in the nucleus, simultaneously with increasing activated 4E-BP1 in the nucleus (Fig. 5D and Supplementary Fig. S1 ).
The biguanide-induced 4E-BP1 hyperactivation during glucose deprivation is considered to occur through mTOR inhibition. Consistently, biguanides have been reported to inhibit mTOR signaling through AMPK-dependent and AMPK-independent mechanisms (19, 20) . Glucose withdrawal can also suppress the mTOR signaling pathway (6) . Of importance, we found that the inhibitory effects on the mTOR signaling pathway are strongly enhanced by the combination of biguanides and glucose withdrawal. The precise mechanisms behind the enhanced mTOR inhibition remain to be clarified; however, there are some clues to understanding them. As shown in Fig. 1E , the combined effects of biguanides and glucose withdrawal seem to be independent of AMPK activation. We recently found that mitochondrial dysfunction not only leads to failure of UPR activation with increased cell death but also to 4E-BP1 hyperactivation during glucose deprivation (ref. 34 ; data not shown). Consistently, it has been reported that biguanides can induce mitochondrial dysfunction (35, 36) . Thus, mitochondrial dysfunction may play an important role in enhanced mTOR inhibition leading to 4E-BP1 hyperactivation when cells are treated with biguanides during glucose deprivation.
In summary, we have shown that hyperactivation of 4E-BP1 is a mediator for biguanides that prevent the UPR and exert antitumor cytotoxicity during glucose deprivation. Importantly, such biguanide-induced 4E-BP1 hyperactivation can also be induced in xenoplanted cancer cells, suggesting that glucose levels in the xenografts could be low enough for the drug action. Further studies will be needed to show whether the druginduced 4E-BP1 hyperactivation can be widely seen in the other tumor models, including orthotopic tumor models. In the meantime, it is widely recognized that glucose deprivation generates resistance to many clinically important antitumor drugs in a variety of human cancer cells (7, 37, 38) . The development of drug resistance is closely associated with UPR activation (7) . Thus, the action of biguanides via 4E-BP1 may be useful to eliminate otherwise drug-resistant, glucose-deprived tumor cells. Our findings have also shown that the biguanide-induced 4E-BP1 hyperactivation can be mediated by a strong inhibition of the mTOR signaling pathway. Recently, the success of rapamycin and its analogs as anticancer agents has motivated the developments of other types of mTOR inhibitors (2) . In this context, biguanides may be interesting as a unique type of antitumor agent that suppresses the mTOR signaling pathway during glucose deprivation. Considering their activities on 4E-BP1 activation, buformin and 
